全球糖尿病設備及藥物市場(2011∼2016年) 是由出版商Transparency Market Research在2011年11月所出版的。
這份英文市場調查報告書包含Pages: 122 價格從美金4395起跳。
全球糖尿病管理市場2010年達到400億美元的市場規模，今後將以年複合成長率13.5％持續擴大，預計規模將達到1,140億美元。美國為主要的收益來源，佔據全收益的35％。但由於以中國為首的亞太地區的經濟發展，今後10年美國市場將減少5∼7％。
本報告提供全球糖尿病市場相關調查，到2016年為止的市場規模與預測，各地區趨勢，產業內的合併·收購趨勢等彙整資料，為您概述為以下內容。
第1章 市場概要
第2章 市場指標
第3章 市場分析
- 美國的糖尿病市場
- 歐洲市場
- 技術創新促進歐洲市場成長
- 阻礙要素
- 歐洲各國的未診斷患者
- 高漲的研究開發成本
- 機會
- 市場規模與成長率
- 亞太地區的糖尿病市場
- 市場概要
- 中國
- 印度
- 韓國
- 台灣
- 市場規模與成長率
第4章 全球糖尿病設備市場
第5章 競爭分析
第6章 全球糖尿病藥物市場
- 市場概要
- 全球糖尿病投入的藥劑市場
- 市場規模與成長率
- 促進因素
- 改善的給藥設備
- 口服糖尿病藥物的風險增加
- 技術的進步
- 阻礙要素
- 機會
- 全球胰島素市場
- 口服糖尿病藥物市場
- 市場規模與成長率
- 全球受歡迎的抗糖尿病藥物
- 促進因素
- 阻礙要素
- 機會
第7章 企業簡介
- Abbott Laboratories
- Bristol-Myers Squibb (BMS)
- Dexcom
- Eli Lilly
- GlaxoSmithKline
- Glenmark Pharmaceuticals
- Johnson&Johnson
- Lupin
- Roche
- Sanofi
ABSTRACT
Description
The report contains the global scenario of Diabetes market discussing its details and market figures. The report provides market size and forecast till 2016 for each segment and geography across the globe. It also describes the key influencing factors for Diabetes market. The report lists mergers & acquisitions among the major players along with key product developments in the market. The report also provides information about major players in the market as company profiles.
MARKET OVERVIEW
The Global Market for Diabetes Management accounted for USD 40 billion in 2010 and is expected to attain a market size of around USD 114 billion following a growth rate of 13.5% CAGR. The major products in this market consists of glucose meters, test strips, lancets, continuous blood glucose meters, syringes, insulin pumps, insulin and other insulin delivery devices and anti-diabetic drugs. However, insulin, test strips and anti-diabetic drugs are the most revenue generating products.
Among the different geographies across the globe, U.S. forms the main source of revenue for this market contributing for around 35% of the revenue. However, with the continuous economic growth of Asia-Pacific region especially that of China, the contribution of U.S. market is expected to drop by 5% to 7% with a period of 10 years from now.
Currently more than 275 million people are suffering from diabetes across the globe and this population is expected to exceed 425 million by 2030. As per the present scenario, the population within the age bracket of 40-59 years is the most affected. However, this age bracket is expected to shift to the age-group 60-79 years by 2030.
Out of the two major segments of Diabetes market globally, the Diabetes drug market accounts for approximately USD 28 billion with oral drug constituting around 38% and injectables contributing more than 55%. The other major segment of the global diabetes market, the device market, accounted for USD 16 billion in year 2010.
With the increase in population and change in lifestyle which is leading to obesity, the diabetic population is increasing rapidly. Also the lack in awareness about the Diabetes diagnostics and treatment, the countries with high population are leading to the expansion in the diabetic population worldwide.
With the participation of Pharma giants, this market is characterized as highly competitive market. The major players in Diabetes drugs market worldwide includes Abbott Laboratories, Novo Nordisk, Merck, Sanofi-Aventis etc. and those in device market include Johnson & Johnson, Roche, Bayer, Zydus Cadila etc.
TABLE OF CONTENTS
Table Of Content
Chapter 1 Market Overview
Chapter 2 Market Metrics
- 2.1 Prevalence of Diabetes
- 2.2 Age-Group Analysis
Chapter 3 Market Analysis
- 3.1 U.S. Diabetes Market
- 3.1.1 Drivers
- 3.1.1.1 Increase in awareness among diabetic population
- 3.1.1.2 Obesity as a leading cause of diabetes
- 3.1.2 Restraints
- 3.1.2.1 Undiagnosed Diabetic population
- 3.1.3 Opportunities
- 3.1.3.1 Increasing awareness may unleash the untapped market potential
- 3.1.4 Key Market Trends
- 3.2 EUROPEAN MARKET
- 3.2.1 Innovation driving the European market
- 3.2.1.1 Restraints
- 3.2.1.1.1 Case1
- 3.2.1.1.2 Case 2
- 3.2.1.1.3 Case 3
- 3.2.1.2 Undiagnosed patients high in European countries
- 3.2.1.3 Increasing R&D costs
- 3.2.2 Opportunities
- 3.2.2.1 Undiagnosed Diabetic Patient Population in Europe
- 3.2.3 Market Size & Growth rate
- 3.3 Asia-Pacific Diabetes Market
- 3.3.1 Market Overview
- 3.3.2 China
- 3.3.3 India
- 3.3.4 South Korea
- 3.3.5 Taiwan
- 3.3.6 Market Size & Growth rate
Chapter 4 Global Diabetes Device Market
- 4.1 Insulin Pumps
- 4.1.1 Drivers
- 4.1.1.1 Growing Diabetic Population
- 4.1.1.2 Advancement in Technology
- 4.2 Global Self Monitoring Blood Glucose Market
- 4.2.1 Market Size & Growth Rate
- 4.2.1.1 Drivers
- 4.2.1.1.1 Increasing awareness and simpler devices
- 4.2.1.1.2 Increase in disposable income
- 4.2.1.1.3 Declining prices
- 4.2.1.1.4 Improving compatibility
- 4.2.1.2 Restraints
- 4.2.1.2.1 Increase in competition leading to low prices
- 4.2.1.2.2 Private Label Brands
- 4.2.1.2.3 Awareness among patients is still a challenge
- 4.2.2 Key trends
Chapter 5 Competition Analysis
- 5.1 Continuous Glucose Monitor Market
- 5.1.1 Drivers
- 5.1.2 Restraints
- 5.1.3 Opportunity
- 5.2 Clinical Trials
Chapter 6 Global Diabetes Drugs Market
- 6.1 Market Overview
- 6.1.1 Market Size and Growth Rates
- 6.2 Global Diabetes Injectables Market
- 6.2.1 Market Size & Growth rate
- 6.2.2 Drivers
- 6.2.2.1 Improved Delivery Devices
- 6.2.2.2 Increased risk with the Oral Anti-Diabetes Drugs
- 6.2.2.3 Technological Advancement
- 6.2.3 Restraints
- 6.2.3.1 Associated Pain
- 6.2.3.2 Market boom for New Generation diabetic drugs
- 6.2.3.3 Cost Issues
- 6.2.4 Opportunities
- 6.2.4.1 Novel insulin delivery method
- 6.3 Global Insulin Market
- 6.3.1 Global Non-Insulin Injectables Market
- 6.3.1.1 Drivers
- 6.3.1.2 Opportunities
- 6.4 Global Oral diabetes Drug Market
- 6.4.1 Market Size & Growth rate
- 6.4.2 Popular Anti-Diabetic Drugs World wide
- 6.4.3 Drivers
- 6.4.3.1 Novel drugs driving the market growth
- 6.4.3.2 Patent expiry of popular drugs
- 6.4.3.3 Painless Option
- 6.4.4 Restraints
- 6.4.4.1 Associated High Risks
- 6.4.4.2 Improving options of insulin delivery devices
- 6.4.4.3 Trend of diabetic diet
- 6.4.5 Opportunities
- 6.4.5.1 Diabetes Vaccines
- 6.4.5.2 Leveraging the patent expiry of popular drugs
Chapter 8 Company Profiles
- 8.1 Abbott Laboratories
- 8.2 Bristol-Myers Squibb (BMS)
- 8.3 Dexcom
- 8.4 Eli Lilly
- 8.5 GlaxoSmithKline
- 8.6 Glenmark Pharmaceuticals
- 8.7 Johnson&Johnson
- 8.8 Lupin
- 8.9 Roche
- 8.10 Sanofi
